SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — John Henry Holliday — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientJohn Henry Holliday
Date of birth1851-08-14
IdentifiersMRN HR-NI007-SYN-TD; SSN (made up) 000-07-8153
Document date1873-02-24
AuthorMartin Beaumont, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Two-week follow-up on tuberculosis treatment, seen the same day by infectious diseases. [S]

History of Present Illness

Mr. Holliday is a 21-year-old dentist with cavitary pulmonary tuberculosis who returns two weeks after diagnosis and is seen by infectious diseases today. He started isoniazid, rifampin, pyrazinamide, ethambutol, and pyridoxine two days after the first visit, once the nucleic acid amplification test confirmed tuberculosis, and has taken all thirteen doses on daily video calls with the health department nurse. His cough is less frequent, the blood streaks in his sputum have stopped, and the night sweats are lighter. He has mild nausea in the hour after the morning doses, eased by taking them at bedtime with a small snack. His urine and tears are orange, as he was warned. He has no yellowing, dark urine, abdominal pain, rash, numbness, or change in vision or color. He is isolating at home and not working; his roommate is being tested by the health department. He has cut down to a drink or two on three evenings in the two weeks and has not played cards. He feels low about being away from his practice but has no thoughts of suicide. [S]

ElementDetail
TreatmentThirteen of thirteen doses observed by video
SymptomsLess cough, no further blood in the sputum, lighter night sweats
Side effectsMild nausea after morning doses; orange urine and tears
AlcoholCut down; AUDIT-C 4 for the past two weeks
IsolationAt home; off work

Review of Systems

SystemResultFinding
RespiratoryPositiveCough less frequent; no blood in the sputum for a week; no breathlessness
ConstitutionalPositiveLighter night sweats; no fever for five days; appetite returning
GastrointestinalPositiveMild nausea after doses; no vomiting, abdominal pain, or jaundice
EyesNegativeNo blurred vision or change in color vision
NeurologicalNegativeNo numbness or tingling
PsychiatricPositiveLow about isolation and time off work; no thoughts of suicide or self-harm

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Isoniazid 300 mg tablet, one tablet daily300 mg once daily by video-observed therapy with the health department, seven days a week, for six monthsOral route1873-02-12 to 1873-08-13completedS
Rifampin 300 mg capsules, two capsules (600 mg) daily600 mg once daily on an empty stomach by video-observed therapy with the health department, seven days a week, for six monthsOral route1873-02-12 to 1873-08-13completedS
Pyrazinamide 500 mg tablets, three tablets (1500 mg) daily1500 mg once daily by video-observed therapy with the health department, seven days a week, for the eight-week intensive phaseOral route1873-02-12 to 1873-04-08completedS
Ethambutol 400 mg tablets, three tablets (1200 mg) daily1200 mg once daily by video-observed therapy with the health department, seven days a week, until susceptibility results returnOral route1873-02-12 to 1873-03-10stoppedS
Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily50 mg once daily with isoniazidOral route1873-02-12 to 1873-08-13completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1873-02-24Body height178cmS
1873-02-24Body weight59kgS
1873-02-24Body mass index (BMI) [Ratio]18.6kg/m2S
1873-02-24Systolic blood pressure114mm[Hg]S
1873-02-24Diastolic blood pressure72mm[Hg]S
1873-02-24Heart rate92/minS
1873-02-24Respiratory rate18/minS
1873-02-24Body temperature37.3CelS
1873-02-24Oxygen saturation in Arterial blood by Pulse oximetry96%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1873-02-24Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma41U/L7-56 U/LNormalS
1873-02-24Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma39U/L10-40 U/LNormalS
1873-02-24Bilirubin.total [Mass/volume] in Serum or Plasma0.7mg/dL0.1-1.2 mg/dLNormalS
1873-02-24Visual acuity uncorrected Right eye by ETDRS eye chart85{letters}>=80NormalS
1873-02-24Visual acuity uncorrected Left eye by ETDRS eye chart84{letters}>=80NormalS
1873-02-24Total score [AUDIT-C]4{score}S

Physical Exam

Vital signs recorded on 1873-02-24; see the Vital Signs section. [S]

SystemFinding
GeneralThin, less tired; weight 59.0 kg, up 1.0 kg; temperature 37.3 °C, heart rate 92; seen in a negative-pressure room with a respirator
EyesNo icterus. Visual acuity 85 letters on the right and 84 on the left; Ishihara plates read correctly with each eye
RespiratoryCoarse crackles and bronchial breathing over the right upper zone, less than two weeks ago
AbdomenSoft and non-tender; liver not enlarged
NeurologicalNormal sensation and reflexes in the feet

Problems

ProblemClinical statusVerificationCodeProvenance
Pulmonary tuberculosis, right upper lobe cavitary, sputum smear-positive, confirmed by nucleic acid amplification without rifampin resistanceactiveconfirmed A15.0S — Synthetic modern coding of his documented pulmonary tuberculosis at the time of diagnosis; the bacteriology is synthetic.
Alcohol use disorder, mild, with binge drinkingactiveconfirmed F10.10S — Synthetic modern coding anchored to the documented heavy drinking; the severity and the criteria met are synthetic.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationSymptom review: cough, sputum, hemoptysis, fever, night sweatsAt least monthly during treatmentCompleted todayCough and night sweats improving; no hemoptysis for a week
ExaminationWeightAt least monthly during treatmentCompleted today59.0 kg, up 1.0 kg
Medication safetyHepatitis symptom review (nausea, vomiting, abdominal pain, jaundice, dark urine)Every visit and every observed doseCompleted todayMild nausea only, eased by bedtime dosing; no jaundice, dark urine, or pain
LaboratoryLiver tests (ALT, AST, bilirubin)Baseline, at two weeks, then monthly because of alcohol useCompleted todayALT 41, AST 39 U/L, bilirubin 0.7 mg/dL, all normal
ImagingVisual acuity and color visionBaseline and monthly while on ethambutolCompleted today85 letters on the right and 84 on the left; color vision normal
LaboratoryNucleic acid amplification test with rifampin resistanceAt diagnosisUp to dateMycobacterium tuberculosis detected, rifampin resistance not detected, on the first sample
LaboratorySputum AFB smear and cultureMonthly until two consecutive cultures are negativeCompleted todayBaseline smears 2+, 2+, and 3+; cultures growing Mycobacterium tuberculosis complex; release smears ordered for next week
LaboratoryDrug susceptibility testing of the first isolateOnce, on the first positive cultureOrderedPending on the baseline isolate
LaboratoryHIV testAt diagnosisUp to dateHIV-1/2 antigen and antibody test negative at diagnosis
LaboratoryHepatitis B and C serologyAt diagnosisUp to dateHepatitis B surface antigen, surface antibody, and core antibody negative; hepatitis C antibody negative; not immune to hepatitis B
LaboratoryDiabetes screenAt diagnosisUp to dateHbA1c 5.2 percent at diagnosis
ImagingChest X-rayAt diagnosis; at two months only if the first cultures were negative; at the end of treatment as a new baselineUp to dateRight upper lobe cavity at diagnosis
Medication safetyDoses observed and missed (video-observed therapy)Every visitCompleted todayThirteen of thirteen doses observed
Medication safetyPeripheral neuropathy check, with pyridoxineEvery visitCompleted todayNo neuropathy; pyridoxine 50 mg daily
Medication safetyRifampin drug-interaction reviewWith every new medicineCompleted todayNo other medicines; told that rifampin interacts with many drugs and stains contact lenses
Self-managementHome isolation and the criteria for releaseUntil three negative smears, clinical improvement, and two weeks of treatmentCompleted todayIsolating at home with no visitors; off work
ReferralContact investigation (household, coworkers, patients)Led by the health department, from diagnosisReferredHealth department testing his roommate and assessing coworkers and the patients he treated in the last three months; their results are not part of his record
ReferralReport to the local health departmentAt diagnosisUp to dateReported the day of diagnosis
SurveyAlcohol use (AUDIT-C for the past month)Every visitCompleted todayAUDIT-C 4 for the past two weeks, down from 9
Self-managementBrief counseling about alcohol and liver riskEvery visitCompleted todayAgreed goal of no alcohol during treatment
ReferralCounseling with a substance-use counselorEvery one to two weeks during treatmentOrderedFirst video session next week
Medication safetyMedication for alcohol use disorderOffered for alcohol use disorderNot indicatedAcamprosate offered; he prefers counseling first for a mild disorder
SurveySuicide-risk review and safety plan, with the 988 Suicide & Crisis LifelineEvery visitCompleted todayNo thoughts of suicide; the 988 Suicide & Crisis Lifeline is in his phone
ReferralInfectious diseases consultationOnce at diagnosis, then as advisedCompleted todaySeen today

Goal progress:

Guideline basis: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016); An official ATS statement: hepatotoxicity of antituberculosis therapy (2006); Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC (2005); Unhealthy Alcohol Use in Adolescents and Adults: Screening and Behavioral Counseling Interventions (2018); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024)

Follow-up: Release smears next week. Five-week review with susceptibility results. Call the same day for hepatitis symptoms. Next scheduled visit 1873-03-17: five-week review: susceptibility results, release from isolation, and liver monitoring. [S]